glioblastoma multiforme
Oncology · 2005–2010
4decisions
3medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Use in first or second relapse of glioblastoma multiforme following therapy that includes temozolomide or where temozolomide is contraindicated or not… | Nov 2010 | Not recommended | unclear |
| carmustine treatment of recurrent glioblastoma multiforme (GBM) in patients for whom surgical resection is indicated and recurrence has occurred within 6 months of… | Jul 2008 | Not recommended | no section in document |
| carmustine treatment of recurrent glioblastoma multiforme in patients for whom surgical resection is indicated | Mar 2007 | Not recommended | no section in document |
| carmustine, implant Newly-diagnosed glioblastoma multiforme as an adjunct to surgery and radiation. | Nov 2005 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.